These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18330032)

  • 21. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M; Tomlinson B
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1143-50. PubMed ID: 20872317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 24. Unmet challenges in HIV therapy and potential of stampidine.
    Uckun FM
    Arzneimittelforschung; 2006 Feb; 56(2A):117-20. PubMed ID: 16570820
    [No Abstract]   [Full Text] [Related]  

  • 25. Why HIV drug resistance matters: an overview.
    Learned J
    Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
    [No Abstract]   [Full Text] [Related]  

  • 26. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract]   [Full Text] [Related]  

  • 27. High antiretroviral drug adherence key in effort to avoid drug resistance. New study highlights its importance.
    AIDS Alert; 2005 Mar; 20(3):25, 27-8. PubMed ID: 15789470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accrued HIV evidence turns treatment dogma on its head.
    Check E
    Nature; 2003 Aug; 424(6951):866. PubMed ID: 12931150
    [No Abstract]   [Full Text] [Related]  

  • 30. Electrolyte disturbances may predispose nucleoside analogue-treated AIDS patients to acute renal failure.
    Spichler AS; Seguro AC
    Int J Infect Dis; 2004 Nov; 8(6):377-8. PubMed ID: 15494261
    [No Abstract]   [Full Text] [Related]  

  • 31. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
    Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
    AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible new treatment strategy for HIV/AIDS patients.
    AIDS Read; 2000 Oct; 10(10):578-9. PubMed ID: 11068798
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].
    Cholewińska G
    Przegl Epidemiol; 2008; 62(1):149-54. PubMed ID: 18536238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching antiretroviral therapy: why, when and how.
    Wilkin T; Glesby M; Gulick RM
    IAPAC Mon; 2006 Jul; 12(7):220-9. PubMed ID: 17096494
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV drug resistance.
    Calmy A; Pascual F; Ford N
    N Engl J Med; 2004 Jun; 350(26):2720-1. PubMed ID: 15215494
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.